PPMI at MDS 2015

PPMI is excited to announce that several presentations at the 19th International Congress of Parkinson’s Disease and Movement Disorders (MDS) will feature PPMI data.  Researchers, clinicians, and other health and science professionals in the Parkinson’s and movement disorders field will gather in San Diego, California on June 14-18, 2015 to participate in this meeting.  We invite you to learn the latest scientific updates coming out of PPMI at the following sessions:

SKILLS WORKSHOP

June 16, 6pm: Practical issues in using neuroimaging in Movement Disorders: What, when, why ? Danna Jennings (Location: Seaport Ballroom A-E, 2nd Level, Seaport Tower)

BREAKING NEWS IN MOVEMENT DISORDERS

June 17, 10:30am, Plenary Session 4102: Late-breaking clinical trials and clinical science in Parkinson?s disease – Tanya Simuni (Location: Seaport Ballroom A-E,2nd Level, Seaport Tower)

DETECTING PRODROMAL PARKINSON’S DISEASE

June 17, 3pm, Teaching Course: Imaging and other biomarkers of prodromal Parkinson?s disease ? Ken Marek (Location: Harbor B-C, 2nd Level, Harbor Tower)

PARKINSON?S DISEASE: NEUROIMAGING AND NEUROPHYSIOLOGY

29: Alternations of human brain connectome in Parkinson?s disease using network based statistics (NBS) – A. Kamalian, M.H. Aarabi (Tehran, Iran)

49: Aberrant cerebral network topology and mild cognitive impairment in early Parkinson?s disease – J.B. Pereira, D. Aarsland, C. Ginestet, A. Lebedev, L.O. Wahlund, A. Simmons, G. Volpe, E. Westman (Stockholm, Sweden)

56: Fiber tract atrophy in idiopathic Parkinson?s disease – F.M. Skidmore, T. Anthony, J. Marstrander, Y. Liu, G. Cutter, D. Standaert (Birmingham, AL, USA)

PARKINSON?S DISEASE: PATHOPHYSIOLOGY

81: UPDRS asymmetry is higher for the upper extremities compared to the lower extremities in Parkinson?s disease – G. Foffani, J.A. Obeso (Móstoles, Spain)

PARKINSON?S DISEASE: CLINICAL TRIALS, PHARMACOLOGY AND TREATMENT

317: Can we reliably establish Parkinson?s disease subtypes in de novo patients: Follow up results from the PPMI study – T. Simuni, C.J. Caspell-Garcia, C. Coffey, S. Lasch, D. Jennings, C. Tanner, K. Kieburtz, K. Marek, For the PPMI Investigators (Chicago, IL, USA)

319: One year longitudinal change in the MDS-UPDRS scores in de novo Parkinson?s disease patients: Results from the PPMI study – T. Simuni, C. Caspell-Garcia, C. Coffey, S. Lasch, D. Jennings, C. Tanner, K. Kieburtz, K. Marek, For the PPMI Investigators (Chicago, IL, USA)

PARKINSON?S DISEASE: NON-MOTOR SYMPTOMS

385: Sleep and sleepiness symptoms as predictors of cognitive decline in early Parkinson?s disease: Results from the PPMI study – L.M. Chahine, B. Tran, S. Xie, S. Christi, D. Abi, C. Linder, R. Purri, T. Simuni, G. Murray, W. Daniel (Philadelphia, PA, USA)

399: Olfaction and nonmotor symptoms (NMS) in subjects with scans without evidence of dopaminergic deficit (SWEDDs) – M.E. Fullard, D. Weintraub, J.E. Duda, J.F. Morley (Philadelphia, PA, USA)

400: Relationship between olfaction, motor and nonmotor symptoms and dopamine transporter binding in de novo PD – M.E. Fullard, D. Weintraub, J.E. Duda, J.F. Morley (Philadelphia, PA, USA)

473: Hyposmia as a predictor of non-motor features in patients with de novo Parkinson?s disease – B.L. Tran, L.M. Chahine, J. Rick, M. Christi, D. Abigail, L. Carly, P. Rachael (Philadelphia, PA, USA)

478: Increased odds of bladder and bowel symptoms in early Parkinson?s disease compared to healthy controls – C.P. Vaughan, J.L. Juncos, A.D. Markland, K.L. Burgio, P.S. Goode, T.M. Johnson II (Atlanta, GA, USA)

PARKINSON?S DISEASE: COGNITION

862: POSET based cognitive function impairment (pCFI): A novel approach for delineating heterogeneity of cognitive impairment in Parkinson?s disease – D.K. Gupta, J.G. Goldman, J. Jaeger, C. Tatsuoka (Cleveland, OH, USA)

NEUROIMAGING

968: Parkinson?s progression markers initiative (PPMI) prodromal cohort of REM behavior disorder (RBD) with DAT deficit – Parkinson?s Progression Markers Initiative (PPMI) RBD Investigators (New Haven, CT, USA)

980: Comparison of baseline 123-I Ioflupane SPECT striatal binding ratios with diffusion tensor images from the Parkinson?s progression marker initiative – C.L. Gallagher, J. Sojkova, B.B. Bendlin, O. Okonkwo, A. Alexander, I.W. Wu, N. Schuff (Madison, WI, USA)

PARKINSON?S DISEASE: GENETICS

1038: The tyrosine hydroxylase Val81Met polymorphism is associated with motor symptom severity in de novo patients with Parkinson?s disease – J. Kraemmer, F. Cormier-Dequaire, A. Brice, J.C. Corvol, PPMI Genetic Working Group (Paris, France)

THERAPY IN MOVEMENT DISORDERS: MEDICAL

1107: The Parkinson?s progression marker initiative (PPMI) ? Developing a sample size estimate for Parkinson?s disease therapeutic trials – Parkinson?s Progression Marker Initiative (New Haven, CT, USA)

GENETICS

1162: Novel recruitment strategy to enrich for LRRK2 mutation carriers – T. Foroud, D. Smith, J. Jackson, J. Verbrugge, C. Halter, L. Wetherill, K. Sims, W. Xin, V. Arnedo, S. Lasch, K. Marek (Indianapolis, IN, USA)

PHENOMENOLOGY AND CLINICAL ASSESSMENT OF MOVEMENT DISORDERS

1194: Physical activity correlates with disease severity among new onset Parkinson?s disease patients – P. Gonzalez-Latapi, J.D. Ciolino, T. Simuni (Boston, MA, USA)

MICHAEL J. FOX FOUNDATION TABLE

More information about PPMI and the resources available to qualified researchers will also be at The Michael J. Fox Foundation’s booth located at table 10 outside the exhibit hall.